No increased risks associated with propranolol treatment for infantile hemangioma in preterm infants were identified at 3 years of age, notes a study published in the American Journal of Clinical Dermatology.
In the study, researchers assessed 55 preterm and 180 term newborns to estimate the incidence of long-term unfavorable outcomes and growth impairment after use of propranolol for treatment of infantile hemangioma (IH).
They observed no significant differences in terms of general features like height and weight among preterm candidates. But, 1-year-old female weight and head circumference were found notably higher than the normal references among children born at term.
They determined no adverse impacts or complexities up to the age of 3 years in both preterm and term candidates after treatment for IH with propranolol for 6 months.